Concepts (72)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 7 | 2023 | 113 | 2.060 |
Why?
|
| Pancreas Transplantation | 3 | 2023 | 17 | 1.650 |
Why?
|
| Cell-Free Nucleic Acids | 3 | 2023 | 12 | 1.640 |
Why?
|
| Organ Transplantation | 2 | 2022 | 32 | 1.440 |
Why?
|
| Graft vs Host Disease | 2 | 2022 | 53 | 1.390 |
Why?
|
| Graft Rejection | 5 | 2023 | 64 | 0.820 |
Why?
|
| Kidney Failure, Chronic | 2 | 2020 | 121 | 0.680 |
Why?
|
| Tissue Donors | 4 | 2023 | 67 | 0.680 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2023 | 173 | 0.660 |
Why?
|
| Patient Compliance | 1 | 2020 | 146 | 0.600 |
Why?
|
| Immunosuppressive Agents | 2 | 2020 | 113 | 0.430 |
Why?
|
| Islets of Langerhans Transplantation | 2 | 2021 | 3 | 0.350 |
Why?
|
| C-Peptide | 2 | 2023 | 5 | 0.350 |
Why?
|
| Humans | 16 | 2023 | 23175 | 0.350 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 2022 | 22 | 0.350 |
Why?
|
| Retrospective Studies | 7 | 2022 | 2990 | 0.240 |
Why?
|
| Pancreas | 2 | 2023 | 30 | 0.240 |
Why?
|
| Transplant Recipients | 2 | 2023 | 21 | 0.240 |
Why?
|
| Pancreatic Elastase | 1 | 2023 | 5 | 0.200 |
Why?
|
| Weight Gain | 1 | 2023 | 61 | 0.190 |
Why?
|
| Liver Transplantation | 2 | 2014 | 81 | 0.190 |
Why?
|
| Aneurysm | 1 | 2022 | 10 | 0.180 |
Why?
|
| Arteriovenous Fistula | 1 | 2022 | 10 | 0.180 |
Why?
|
| Young Adult | 3 | 2020 | 1656 | 0.180 |
Why?
|
| Adolescent | 3 | 2020 | 1884 | 0.180 |
Why?
|
| Islets of Langerhans | 1 | 2021 | 3 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2021 | 15 | 0.170 |
Why?
|
| Surgical Instruments | 1 | 2020 | 24 | 0.170 |
Why?
|
| Biological Products | 1 | 2021 | 30 | 0.160 |
Why?
|
| Health Care Costs | 1 | 2020 | 61 | 0.160 |
Why?
|
| Suture Techniques | 1 | 2020 | 112 | 0.160 |
Why?
|
| Adult | 5 | 2020 | 6949 | 0.150 |
Why?
|
| Time Factors | 4 | 2022 | 1264 | 0.150 |
Why?
|
| Prognosis | 1 | 2020 | 730 | 0.140 |
Why?
|
| Aged | 4 | 2020 | 7650 | 0.130 |
Why?
|
| Middle Aged | 4 | 2020 | 7970 | 0.130 |
Why?
|
| Male | 6 | 2020 | 12648 | 0.130 |
Why?
|
| Prostatic Neoplasms | 1 | 2017 | 92 | 0.130 |
Why?
|
| Female | 5 | 2020 | 13131 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2022 | 2943 | 0.110 |
Why?
|
| Liver Cirrhosis | 1 | 2014 | 40 | 0.110 |
Why?
|
| Graft Survival | 2 | 2014 | 84 | 0.100 |
Why?
|
| Rectus Abdominis | 1 | 2013 | 3 | 0.100 |
Why?
|
| Abdominal Wall | 1 | 2013 | 6 | 0.100 |
Why?
|
| Surgical Flaps | 1 | 2013 | 50 | 0.090 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 3864 | 0.090 |
Why?
|
| Vascular Patency | 2 | 2022 | 17 | 0.090 |
Why?
|
| Child, Preschool | 2 | 2013 | 569 | 0.090 |
Why?
|
| Renal Dialysis | 2 | 2022 | 82 | 0.080 |
Why?
|
| Risk Factors | 2 | 2022 | 2020 | 0.080 |
Why?
|
| Insulin | 2 | 2021 | 77 | 0.080 |
Why?
|
| Child | 2 | 2013 | 1160 | 0.080 |
Why?
|
| Ireland | 1 | 2009 | 3 | 0.070 |
Why?
|
| Allografts | 2 | 2020 | 147 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 313 | 0.070 |
Why?
|
| Survival Rate | 1 | 2009 | 320 | 0.070 |
Why?
|
| Incidence | 2 | 2021 | 631 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2009 | 1430 | 0.060 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2022 | 19 | 0.050 |
Why?
|
| Transplantation, Heterologous | 1 | 2021 | 20 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2021 | 32 | 0.040 |
Why?
|
| Cost Savings | 1 | 2020 | 29 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 106 | 0.040 |
Why?
|
| Kidney | 1 | 2021 | 142 | 0.040 |
Why?
|
| Prostate-Specific Antigen | 1 | 2017 | 15 | 0.030 |
Why?
|
| United States | 1 | 2021 | 1801 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 550 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2020 | 812 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2014 | 15 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2014 | 226 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2014 | 310 | 0.020 |
Why?
|
| Infant | 1 | 2013 | 483 | 0.020 |
Why?
|